| 1. |
|
|
| 2. |
- Steinacker, J. M., et al.
(author)
-
Global Alliance for the Promotion of Physical Activity: the Hamburg Declaration
- 2023
-
In: Bmj Open Sport & Exercise Medicine. ; 9:3
-
Journal article (peer-reviewed)abstract
- Non-communicable diseases (NCDs), including coronary heart disease, stroke, hypertension, type 2 diabetes, dementia, depression and cancers, are on the rise worldwide and are often associated with a lack of physical activity (PA). Globally, the levels of PA among individuals are below WHO recommendations. A lack of PA can increase morbidity and mortality, worsen the quality of life and increase the economic burden on individuals and society. In response to this trend, numerous organisations came together under one umbrella in Hamburg, Germany, in April 2021 and signed the 'Hamburg Declaration'. This represented an international commitment to take all necessary actions to increase PA and improve the health of individuals to entire communities. Individuals and organisations are working together as the 'Global Alliance for the Promotion of Physical Activity' to drive long-term individual and population-wide behaviour change by collaborating with all stakeholders in the community: active hospitals, physical activity specialists, community services and healthcare providers, all achieving sustainable health goals for their patients/clients. The 'Hamburg Declaration' calls on national and international policymakers to take concrete action to promote daily PA and exercise at a population level and in healthcare settings.
|
|
| 3. |
- Gislason, S.R., et al.
(author)
-
Environmental pressure from the 2014–15 eruption of Bárðarbunga volcano, Iceland
- 2015
-
In: Geochemical Perspectives Letters. - : European Association of Geochemistry. - 2410-3403 .- 2410-339X. ; 1:2015, s. 84 - 93
-
Journal article (peer-reviewed)abstract
- The effusive six months long 2014-2015 Bárðarbunga eruption (31 August-27 February) was the largest in Iceland for more than 200 years, producing 1.6 ± 0.3 km3 of lava. The total SO2 emission was 11 ± 5 Mt, more than the amount emitted from Europe in 2011. The ground level concentration of SO2 exceeded the 350 μg m−3 hourly average health limit over much of Iceland for days to weeks. Anomalously high SO2 concentrations were also measured at several locations in Europe in September. The lowest pH of fresh snowmelt at the eruption site was 3.3, and 3.2 in precipitation 105 km away from the source. Elevated dissolved H2SO4, HCl, HF, and metal concentrations were measured in snow and precipitation. Environmental pressures from the eruption and impacts on populated areas were reduced by its remoteness, timing, and the weather. The anticipated primary environmental pressure is on the surfacewaters, soils, and vegetation of Iceland.
|
|
| 4. |
- Liu, E. J., et al.
(author)
-
Aerial strategies advance volcanic gas measurements at inaccessible, strongly degassing volcanoes
- 2020
-
In: Science advances. - : American Association for the Advancement of Science (AAAS). - 2375-2548. ; 6:44
-
Journal article (peer-reviewed)abstract
- Volcanic emissions are a critical pathway in Earth's carbon cycle. Here, we show that aerial measurements of volcanic gases using unoccupied aerial systems (UAS) transform our ability to measure and monitor plumes remotely and to constrain global volatile fluxes from volcanoes. Combining multi-scale measurements from ground-based remote sensing, long-range aerial sampling, and satellites, we present comprehensive gas fluxes-3760 ± [600, 310] tons day-1 CO2 and 5150 ± [730, 340] tons day-1 SO2-for a strong yet previously uncharacterized volcanic emitter: Manam, Papua New Guinea. The CO2/ST ratio of 1.07 ± 0.06 suggests a modest slab sediment contribution to the sub-arc mantle. We find that aerial strategies reduce uncertainties associated with ground-based remote sensing of SO2 flux and enable near-real-time measurements of plume chemistry and carbon isotope composition. Our data emphasize the need to account for time averaging of temporal variability in volcanic gas emissions in global flux estimates.
|
|
| 5. |
- Seufferlein, T, et al.
(author)
-
[S3-guideline exocrine pancreatic cancer]
- 2013
-
In: Zeitschrift fur Gastroenterologie. - : Georg Thieme Verlag KG. - 1439-7803 .- 0044-2771. ; 51:12, s. 1395-1440
-
Journal article (peer-reviewed)
|
|
| 6. |
- Darabi, H, et al.
(author)
-
Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)
- 2016
-
In: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 6, s. 32512-
-
Journal article (peer-reviewed)abstract
- Genome-wide association studies have found SNPs at 17q22 to be associated with breast cancer risk. To identify potential causal variants related to breast cancer risk, we performed a high resolution fine-mapping analysis that involved genotyping 517 SNPs using a custom Illumina iSelect array (iCOGS) followed by imputation of genotypes for 3,134 SNPs in more than 89,000 participants of European ancestry from the Breast Cancer Association Consortium (BCAC). We identified 28 highly correlated common variants, in a 53 Kb region spanning two introns of the STXBP4 gene, that are strong candidates for driving breast cancer risk (lead SNP rs2787486 (OR = 0.92; CI 0.90–0.94; P = 8.96 × 10−15)) and are correlated with two previously reported risk-associated variants at this locus, SNPs rs6504950 (OR = 0.94, P = 2.04 × 10−09, r2 = 0.73 with lead SNP) and rs1156287 (OR = 0.93, P = 3.41 × 10−11, r2 = 0.83 with lead SNP). Analyses indicate only one causal SNP in the region and several enhancer elements targeting STXBP4 are located within the 53 kb association signal. Expression studies in breast tumor tissues found SNP rs2787486 to be associated with increased STXBP4 expression, suggesting this may be a target gene of this locus.
|
|
| 7. |
|
|
| 8. |
- Galle, Bo, 1952, et al.
(author)
-
NOVAC – Network for Observation of Volcanic and Atmospheric Change, recent developments and present status
- 2011
-
In: 11th IAVCEI-CCVG Gas Workshop, September 1 - 10, 2011, Kamchatka, Russia.
-
Conference paper (peer-reviewed)abstract
- The NOVAC project, funded by European Union, was started in October 2005 with the aim to establish a global network of stations for the quantitative measurement of volcanic gas emissions. The network is based on a novel type of instrument, the Scanning Dual-beam mini-DOAS. Primarily theinstruments will be used to provide new parameters in the toolbox of observatories for gas emission estimates, geophysical research and hazard assessment. In addition, data are exploited for other scientific purposes, e.g. global estimates of volcanic gas emissions, regional to global statistical analysis, and studies of atmospheric chemistry. In particular large scale validation of satellite measurements of volcanic gas emissions will be possible, bringing space-borne observation of volcanoes a significant step forward.The Scanning Dual-beam Mini-DOAS instrument is capable of real-time automatic, unattended measurement of the total emission fluxes of SO2 and BrO from a volcano with better then 5 minutes time resolution during daylight. The high time-resolution of the data enables correlations with othergeophysical data, e.g. seismicity, thus significantly extending the information available for real-time hazard assessment and research. By comparing high time resolution gas emission data with emissions from neighboring volcanoes on different geographical scales, or with other geophysical events (earthquakes, tidal waves) mechanisms of volcanic forcing may be revealed.The network today encompasses 58 instruments installed on 24 volcanoes, including some of the most active and strongest degassing volcanoes in the world.In addition a mobile version of the instrument has been developed intended for rapid deployment at a volcano in relation to a volcanic crisis.The project and its present status will be presented.
|
|
| 9. |
|
|
| 10. |
- Scott, Robert A., et al.
(author)
-
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
- 2016
-
In: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 8:341
-
Journal article (peer-reviewed)abstract
- Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We therefore investigated the association of variants in six genes that encode drug targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted exome sequencing and follow-up in 39,979 individuals by targeted genotyping, with additional in silico follow-up in consortia. We used these data to first compare associations of variants in genes encoding drug targets with the effects of pharmacological manipulation of those targets in clinical trials. We then tested the association of those variants with disease outcomes, including coronary heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant (Ala316Thr; rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP1R agonist therapies. The minor allele was also associated with protection against heart disease, thus providing evidence that GLP1R agonists are not likely to be associated with an unacceptable increase in cardiovascular risk. Our results provide an encouraging signal that these agents may be associated with benefit, a question currently being addressed in randomized controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes can be used to validate therapeutic targets at an early stage in the drug development process.
|
|
